CClinicalTrials.gg
Status unknownNCT05717361Updated Feb 8, 2023

Opioid Sparing Anesthesia in Cervical Spine Surgery

An interventional study of ketamine-lidocaine and Remifentanil in Pain, Postoperative, Pain, Acute and Pain, Chronic, sponsored by Evangelismos Hospital. Status unknown at 1 site in Greece. Open to participants aged 18 Years to 75 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-02-08.

Sponsored by Evangelismos Hospital · Not applicable, Interventional, and Prevention

The sponsor has not verified this record recently (last verified Jan 2023), so the status shown — last known as Recruiting — may be out of date.
Phase
Not applicable
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Study summary

The aim of this double blind randomized study will be to investigate the effect of an opioid-free anesthesia regimen with a mixture of lidocaine and ketamine in the same syringe versus remifentanyl analgesia in cervical spine surgery.

Read the detailed description

Cervical spine surgery is associated with medium pain scores and perioperative disability. Ketamine and lidocaine have all proven but varied analgesic effects. High opioid consumption has been associated with multiple side effects.

This double blind clinical trial aims to investigate the possible reduction of opioid use during lumbar spine surgery by administering ketamine and lidocaine. Sixty patients will be randomly allocated into two groups. The control group will receive a continuous infusion of remifentanil, while the Ketamine-Lidocaine (KL) group will receive a continuous infusion of ketamine and lidocaine, during the surgery and shortly after.

Both infusions will be administered blindly. Fentanyl and morphine will be administered to each patient so as to maintain hemodynamic stability and pain relief. The study will eventually compare the need for bolus doses of fentanyl during the surgery and morphine shortly after in each group.

Multiple hemodynamic parameters, analgesic consumption, possible side effects, patient satisfaction and the Oswestry low back pain disability questionnaire will be recorded.

02

Conditions studied

  • Pain, Postoperative
  • Pain, Acute
  • Pain, Chronic
  • Pain, Nociceptive
  • Ketamine
  • Lidocaine
  • Analgesia
  • Analgesics
  • Cervical Spine Surgery
03

In context

Pain, Postoperative

5,093 studies on the registry are indexed under Pain, Postoperative; 1,140 are open to participants now.

This study's planned enrollment of 60 is below the median of 75 across 4,344 interventional studies indexed under Pain, Postoperative.

Browse Pain, Postoperative studies →

Lead sponsor

Evangelismos Hospital is the lead sponsor of 28 studies on the registry; 6 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Inclusion criteria

  • Adult patents
  • American Society of Anesthesiologists (ASA) class I-III
  • elective spine surgery

Exclusion criteria

Exclusion Criteria:

  • body mass index (BMI) >35 kg/m2
  • contraindications to local anesthetic administration
  • systematic use of analgesic agents preoperatively
  • chronic pain syndromes preoperatively
  • neurological or psychiatric disease on treatment
  • pregnancy
  • severe hepatic or renal disease
  • history of cardiovascular diseases/ arrhythmias/ conduction abnormalities
  • bradycardia(\<55 beats/minute)
  • drug or alcohol abuse
  • language or communication barriers lack of informed consent
05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
60 participants (estimated)

Study arms

  • Active comparator
    ketamine-lidocaine (KL) group combination of ketamine and lidocaine in one syringe

    Drug: ketamine-lidocaine

  • Active comparator
    : remifentanil group syringe of remifentanil

    Drug: Remifentanil

Interventions

  • Drugketamine-lidocaine

    In the KL group, patients will be administered in a total volume of 20 mL,1mL/10 kg of the solution containing ketamine, lidocaine at predefined concentrations. As maintenance, they will be receiving 1mL/10kg/h of the aforementioned solution

    Also known as: KL group

  • DrugRemifentanil

    In the Remifentanil group, patients will be administered in a total volume of 20 mL, 2 mcg/kg of fentanyl. As maintenance, they will be receiving 1 mL/10kg/h of a remifentanil solution

    Also known as: Remifentanil group

06

What researchers measure

Primary outcomes

  1. pain score on arrival to Post-Anesthesia Care Unit (PACU)

    pain score by the use of Numeric Rating Scale (NRS) on arrival to PACU, ranging from 0 to 10, where 0 means "no pain" and 10 means "worst pain imaginable"

    Time frame: immediately postoperatively]

  2. pain score at discharge from Post-Anesthesia Care Unit (PACU)

    pain score by the use of Numeric Rating Scale (NRS) at discharge from PACU, ranging from 0 to 10, where 0 means "no pain" and 10 means "worst pain imaginable"

    Time frame: at discharge from Post Anesthesia Care Unit (PACU), approximately 1 hour postoperatively

  3. pain score 3 hours postoperatively

    pain score by the use of Numeric Rating Scale (NRS) 3 hours postoperatively, ranging from 0 to 10, where 0 means "no pain" and 10 means "worst pain imaginable"

    Time frame: 3 hours postoperatively

  4. pain score 6 hours postoperatively

    pain score by the use of Numeric Rating Scale (NRS) 6 hours postoperatively, ranging from 0 to 10, where 0 means "no pain" and 10 means "worst pain imaginable"

    Time frame: 6 hours postoperatively

  5. pain score 24 hours postoperatively

    pain score by the use of Numeric Rating Scale (NRS) 24 hours postoperatively, ranging from 0 to 10, where 0 means "no pain" and 10 means "worst pain imaginable"

    Time frame: 24 hours postoperatively

Secondary outcomes

  1. sedation on arrival to Post-Anesthesia Care Unit

    sedation will be assessed with a 5-point sedation scale, where: 1, patient perfectly conscious; 2, patient feels a little drowsy; 3, patient seems to be sleeping but immediately reacts to verbal stimulation; 4, patient seems to be sleeping but slowly reacts to verbal stimulation and 5, patient seems to be sleeping and does not react to verbal stimulation but does react to a stimulus such as shaking or pain

    Time frame: immediately postoperatively

  2. sedation at discharge from Post-Anesthesia Care (PACU) Unit

    sedation will be assessed with a 5-point sedation scale, where: 1, patient perfectly conscious; 2, patient feels a little drowsy; 3, patient seems to be sleeping but immediately reacts to verbal stimulation; 4, patient seems to be sleeping but slowly reacts to verbal stimulation and 5, patient seems to be sleeping and does not react to verbal stimulation but does react to a stimulus such as shaking or pain

    Time frame: at discharge from Post Anesthesia Care Unit (PACU), approximately 1 hour postoperatively

  3. time to first request for analgesia

    the time for the first patient request for analgesia will be noted

    Time frame: during stay in Post-Anesthesia Care Unit (PACU), approximately 1 hour postoperatively

  4. morphine consumption in Post-Anesthesia Care Unit (PACU)

    mg of morphine requested during patient PACU stay

    Time frame: immediately postoperatively

  5. tramadol consumption in the first 48 hours

    patients will be followed for cumulative tramadol consumption for 48 hours postoperatively

    Time frame: 48 hours postoperatively

  6. fentanyl requirement during surgery

    dose of required fentanyl intraoperatively to maintain systolic arterial blood pressure and heart rate within the 20% of baseline value

    Time frame: intraoperatively

  7. satisfaction from postoperative analgesia

    satisfaction from postoperative analgesia on a six-point Likert scale with 1 marked as minimal satisfaction and 6 as maximal satisfaction

    Time frame: 24 hours postoperatively

07

Study locations

1 of 1 sites recruiting
  • Evangelismos General Hospital
    Athens, Greece
    • Athanasios Vaiopoulos · Contact
    • Kassiani Theodoraki, PhD, DESA · Principal investigator
    • Athanasios Vaiopoulos · Sub investigator
    Recruiting
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Feb 8, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05717361
Lead sponsor
Evangelismos Hospital
Collaborators
Aretaieion University Hospital
Responsible party
Athanasios Vaiopoulos (Anesthesia Resident, Evangelismos Hospital) — Principal investigator
First posted
Feb 8, 2023
Start date
Nov 1, 2022
Primary completion
Nov 1, 2024 (estimated)
Completion
Nov 1, 2024 (estimated)
Last update
Feb 8, 2023

Study contacts

Kassiani Theodoraki, PhD, DESA
Contact
ktheodoraki@hotmail.com
+306974634162
Athanasios Vaiopoulos
Contact
thanasisvaio@gmail.com
Kassiani Theodoraki
principal investigator · Aretaieion University Hospital, Athens, Greece

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Jan 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion